Recent Updates
Recently added Catalysts

GlaxoSmithKline Biologicals' influenza vaccine GSK576389A

Phase 2

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 8, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment2,007

FDA Designations

No designations recorded

Clinical trial landscape

GlaxoSmithKline Biologicals' influenza vaccine GSK576389A · 1 trial · 1 indication

Phase 2 1
NCT00540592Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389AInfluenza
COMPLETED2,007 Analytics
PHASE2COMPLETED
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

Haemagglutination Inhibition (HI) Antibody Titers
At Day 21

Antibody titers were expressed as Geometric mean titers (GMTs) against each of the 3 vaccine strains in greater than or equal to 65 years age groups only. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.

Secondary Endpoints

HI Antibody Titers at Day 0 and Day 21
At Day 0 and 21
HI Antibody Titers at Day 180
At Day 180
The Number of Subjects Seroconverted to HI Antibodies at Day 21
At Day 21
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Influenza vaccine GSK576389A formulation 1 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 2 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 3 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 4 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 5 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 6 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 7 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
Influenza vaccine GSK576389A formulation 8 GroupEXPERIMENTALSubjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
Fluarix elderly GroupACTIVE_COMPARATORSubjects aged ≥65 years received one dose of Fluarix vaccine.
Fluarix young GroupACTIVE_COMPARATORSubjects aged 18-40 years received one dose of Fluarix vaccine.

Interventions

NameTypeDescription
GlaxoSmithKline Biologicals' influenza vaccine GSK576389ABIOLOGICALSingle dose, Intramuscular injection, 8 different formulations were tested (one per group)
FluarixBIOLOGICALSingle dose, Intramuscular injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites30

Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female aged 18-40 years old or 65 years or older at the time of the vaccination. * Written informed consent obtained from the...

Countries:GermanyNetherlandsSwedenUnited Kingdom
Unlock Eligibility Criteria